yes

does investors just lose their investment when something like this happens.

11:44 ANPIQ Angiotech Pharmaceuticals, Inc. Common Shares 5/18/2011 100 Plan of Bankruptcy effective. All shares have been cancelled. Deletion Time 11: 40:50 **

Someone just slammed the ask for 400K @.0249¢

haha thanks man, I am just as lost reading through the statements.
Just making sure Im not the only one

if the new is correct..ANPIQ will take a great bounce....good point now for inside!!! ANPIQ BOUNCE!!!!!!!

It's a mess. Seemed to be a good company with outstanding products, but as we see too often now a days they suffered from too much debt and careless management.
The best I can tell is that they have finally reached an agreement with creditors and have issued new FRN's in exchange for outstanding debt, Wells Fargo has taken over assets creating something called a DIP Facility (Debtor In Possession). If I read and understand correctly a complete restructuring of the company, new issue of stock, and new board members. Can't find anything definite about current equity-holders. But it don't look to good.
There are tons of articles and opinions if you google angiotech bankruptcy. Their website has links to A&M's website were they have a document history of petitions filed. Fortunately for me, I only have a small stake in the company, so I will hold on to see what comes of all this. It'll be a learning experience.

Bruce, could you kindly give me a quick rundown of whats going on here?
It would be much appreciated.

Affected Creditors Unanimously Approve Second Amended and Restated CCAA Plan of Compromise or Arrangement
VANCOUVER, April 4 /CNW/ - Angiotech Pharmaceuticals, Inc. ("Angiotech" or the "Company") today announced that the affected creditors of Angiotech and certain of its subsidiaries (collectively, the "Angiotech Entities") have unanimously approved the Second Amended and Restated Plan of Compromise or Arrangement (as amended from time to time, the "Amended Plan") concerning, affecting and involving the Angiotech Entities pursuant to the Companies' Creditors Arrangement Act (Canada).

The Angiotech Entities are scheduled to seek an order of the Supreme Court of British Columbia (the "Court") sanctioning the Amended Plan on April 6, 2011. Should the Court approve the Amended Plan, the Angiotech Entities will proceed with the implementation of the Amended Plan following the satisfaction or waiver of all conditions precedent.

At the meeting of affected creditors today, Alvarez & Marsal Canada Inc. (the "Monitor"), in its capacity as the Court-appointed monitor, reported that 100% of the votes registered by the Angiotech Entities' affected creditors were in favour of the Amended Plan.

To be accepted, the Amended Plan required approval by a majority in number representing at least two-thirds of the total value of the affected creditors' voting claims.

More information about the Angiotech Entities' restructuring process can be found at http://www.angiotech.com and on the website of the Monitor, at http://www.alvarezandmarsal.com/angiotech.

Angiotech Pharmaceuticals, Inc. Announces Amendments to Articles in connection with Implementation of CCAA Plan of Compromise or Arrangement
April 3, 2011 6:29:45 PM PDT
VANCOUVER, April 3 /CNW/ - Angiotech Pharmaceuticals, Inc. ("Angiotech" or the "Company") today announced that, in connection with its previously announced creditor protection proceedings under the Companies' Creditors Arrangement Act (Canada) (the "CCAA Proceedings"), upon implementation of the Second Amended and Restated CCAA Plan of Compromise or Arrangement (as amended from time to time, the "Amended Plan") concerning, affecting and involving Angiotech and certain of its subsidiaries (the "Angiotech Entities") certain additional amendments (the "Additional Amendments") will be made to the Company's articles.

In particular, the Company's articles will be amended to provide that:

Subject to certain exceptions, holders (the "New Common Shareholders") of the Company's new common shares to be issued pursuant to the Amended Plan (the "New Common Shares") will generally be afforded pre-emptive rights with respect to certain future equity issuances by the Company prior to any initial public offering;
Subject to a de minimis exception, in connection with any sale by a New Common Shareholder that owns 45% or more of the outstanding New Common Shares, tag along rights will be provided to other New Common Shareholders to allow them to participate in such sale should they elect to do so;
Any offer by the Company to purchase or redeem any of its New Common Shares shall be made to all New Common Shareholders on a pro rata basis, subject to an exception relating to purchases pursuant to management incentive or other stock-based compensation plans;
Any going private transaction will require the approval of the board of directors as well as a fairness opinion;
Any transaction between the Company and a New Common Shareholder (a "Special Majority Shareholder") holding, alone or with its affiliates, 66?% or more of the outstanding New Common Shares may not be completed unless (i) it is on arm's length terms; and (ii) if the transaction involves consideration in excess of $25 million, the Company has obtained a fairness opinion in respect of such transaction. In addition, if any such transaction requires approval by special resolution, such transaction must also be approved by an ordinary resolution passed by the New Common Shareholders, excluding any Special Majority Shareholder;
The initial term of each member of the new board of directors appointed in connection with the CCAA Proceedings will expire upon the election or appointment of new directors at the Company's third annual shareholders' meeting following the implementation the Amended Plan;
The size of the board of directors will be set at seven members, subject to adjustment by special resolution; and
Shareholders' meetings may be held at any place inside or outside Canada as designated by the board of directors.
Alvarez & Marsal Canada Inc. (the "Monitor"), as Monitor of the Angiotech Entities in the CCAA Proceedings, as well as the holders of a majority of the aggregate outstanding principal amount of the Company's 7.75% Senior Subordinated Notes due 2014, have respectively consented to the implementation of the Additional Amendments. As contemplated by the Amended Plan, the Additional Amendments will be filed with the Supreme Court of British Columbia in advance of the meeting of the Angiotech Entities' creditors to be held on April 4, 2011.

More information about the Angiotech Entities' restructuring process, including the text of the Additional Amendments, can be found at www.angiotech.com and on the website of the Monitor, at http://www.alvarezandmarsal.com/angiotech.

The above descriptions of the Additional Amendments do not purport to be complete statements of the Additional Amendments. The above descriptions of the Additional Amendments are qualified in their entirety by reference to the Additional Amendments, copies of which can be found at www.angiotech.com and on the website of the Monitor, at http://www.alvarezandmarsal.com/angiotech.

is .38 canaidan or us? now i'm up I think - who told me about this one I have no clue - yes no clue on this one.

Sweet, new Q

DTCC : ANPI to ANPIQ :

http://www.dtcc.com/downloads/legal/imp_notices/2011/nscc/otc/OTC-025.pdf

So ANPI is not part of the ANPI.TO? Same animal isnt it?

I meant, the terms are still in negotiation and that can mean anything...

Bk is an option... not cemented yet, and I think they will try to avoid it to save all the company owned shares... you never know what kind of "creative" financing they can come up with at rates close to -0-... see you mon.

This will bounce up nicely in the U.S on Monday ( ANPI ). Not bad news at all; unless you are a Canadian. Michigan born and proud of it!!!

ANPI, filed BK. ANP.to, is halted today, but Bids/Asks: $0.01 for both.

Once ANP.to is resumed, it should be $0.05-0.01 as the Canadian BK stocks usually do.

UPDATE 2-Canada's Angiotech to file for bankruptcy

Angiotech Pharmaceuticals, Inc.

Fri Jan 28, 2011 10:16am EST

* Says recapitalization deal to cut debt by $250 mln

* Deal supported by majority of subordinated noteholders

* Lines up $25 mln DIP loan

* Existing shareholders to be wiped out (Adds details of settlement with former stockholders of Quill Medical)

Jan 28 (Reuters) - Angiotech Pharmaceuticals Inc (ANP.TO) said it will file for bankruptcy protection under Canada's Companies' Creditors Arrangement Act to cut $250 million of its debt.

All of the company's existing shareholders will be wiped out without any compensation under a proposed recapitalization deal. The transaction is supported by noteholders representing more than 84 percent of the outstanding subordinated notes.

The Vancouver-based company, a specialty pharmaceutical and medical device maker, has been hit hard by declining sales of its Taxus coronary stent systems.

Angiotech has also lined up a $25 million debtor-in-possession loan from Wells Fargo Capital Finance LLC to continue operations while under creditor protection.

Under the proposed plan, noteholders will exchange their subordinated notes for a share in 96 percent of the reorganized company's common stock, Angiotech said in a statement.

The company has also agreed to pay $6 million to former shareholders of Quill Medical Inc to settle a lawsuit filed last October.

The lawsuit alleged that Angiotech, which acquired Quill Medical in 2006, misrepresented or made omissions during negotiations for the merger. (Reporting by Santosh Nadgir in Bangalore; Editing by Sriraj Kalluvila and Gopakumar Warrier)

Bounce Play here! Great opportunity to benefit on Monday morning. Clearly an overaction to not bad news. The shorters will be chasing this one back up you watch!! Easy 75 - 100% return in a couple of days IMHO. Do your own DD on this one.

getting impatient with this one

This is bottom.Should be up from here.Tax selling over.Buy back starts.IMO

ANPI news

New Delhi, Dec. 29 -- USA based Afmedica Inc filed patent application for combination drug therapy for reducing scar tissue formation. The inventors are Shebuski Ronald J, Ludere Jack R and Fischell Tim A.

Afmedicainc filed the patent application on Dec. 26, 2006. The patent application number is 3904/KOLNP/2006 A. The international classification numbers are A61K31/4745 and A61F2/00.

According to the Controller General of Patents, Designs & Trade Marks, "The present invention describes various devices and methods wherein a cytostatic antiproliferative drug, either alone or in combination with other drugs, is placed between internal body tissues to prevent the formation of scar tissue and/or adhesions during healing of a wound or surgical site. Specific devices to achieve this administration include, but are not limited to, a permanent implant or a biodegradable material having an attached antiproliferative drug such as sirolimus. These antiproliferative drugs may be combined with other drugs including, but not limited to, antiplatelets, antithrombotics or anticoagulants. The present invention also contemplates methods to a reduce scar tissue and/or adhesions or adhesion formation at an anastomosis site. In particular, a cytostatic antiproliferative drug is administered to an arteriovenous shunt anastomoses in patients having end- stage renal disease."

Afmedica, Inc., a life-sciences company, focuses on drug/device products to prevent cardiovascular complications that occur following surgery. The company engages in commercializing anti-proliferative cyto-static drugs, such as sirolimus on various devices for the prevention of scar tissue formation after surgical procedures. It also develops perivascular technology using the drug rapamycin to treat peripheral vascular, coronary artery, and end stage renal diseases. The company was founded in 2002 and is based in Kalamazoo, Michigan. As of October 7, 2005, Afmedica, Inc. operates as a subsidiary of Angiotech Pharmaceuticals, Inc.

This all I could find from December 22, 2010

FOR IMMEDIATE RELEASE
PRESS RELEASE
December 22, 2010
Angiotech Pharmaceuticals, Inc. Announces Agreement to Extend Cure Period
Under Subordinated Note Indenture
Vancouver, BC, December 22, 2010 – Angiotech Pharmaceuticals, Inc. (NASDAQ:
ANPI; TSE: ANP) (“Angiotech” or the “Company”) today announced that it and U.S.
Bank National Association, as successor trustee under the Company’s subordinated note
indenture, dated as of March 23, 2006 (as amended, supplemented or otherwise modified
from time to time, the “Subordinated Note Indenture”), at the direction of a majority of
the holders of the Company’s 7.75% Senior Subordinated Notes due 2014 (the
“Subordinated Notes”), have executed a supplement to the Subordinated Note Indenture
(the “Supplemental Indenture”). The Supplemental Indenture extends the grace period
applicable to interest payments due on the Subordinated Notes from 90 days to 120 days
before an event of default occurs. The Subordinated Note Indenture was previously
amended on October 29, 2010 and November 29, 2010 to extend this grace period to 60
days and 90 days, respectively.
The Supplemental Indenture will be filed by the Company on both SEDAR and EDGAR,
and the description of the Supplemental Indenture contained in this press release is
qualified by the full text of the Supplemental Indenture.
Forward Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation
statements containing the words “believes,” “may,” “plans,” “will,” “estimates,” “continues,” “anticipates,”
“intends,” “expects” and similar expressions, constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995 and constitute “forward-looking information”
within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the
“safe harbor” provisions of applicable securities legislation. Forward-looking statements may involve, but
are not limited to, comments with respect to our objectives and priorities for the remainder of 2010 and
beyond, our strategies or future actions, our targets, expectations for our financial condition and the results
of, or outlook for, our operations, research and development and product and drug development. Such
forward-looking statements involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Many such known risks,
uncertainties and other factors are taken into account as part of our assumptions underlying these forwardlooking
statements and include, among others, the following: general economic and business conditions in
the United States, Canada and the other regions in which we operate; market demand; technological
changes that could impact our existing products or our ability to develop and commercialize future
products; competition; existing governmental legislation and regulations and changes in, or the failure to
comply with, governmental legislation and regulations; availability of financial reimbursement coverage
from governmental and third-party payers for products and related treatments; adverse results or
unexpected delays in pre-clinical and clinical product development processes; adverse findings related to
the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of
decisions, made by health regulatory agencies regarding approval of our technology and products; the
requirement for substantial funding to conduct research and development, to expand manufacturing and
commercialization activities; and any other factors that may affect our performance. In addition, our
- 2 -
business is subject to certain operating risks that may cause any results expressed or implied by the
forward-looking statements in this press release to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical
and clinical development of our products; changes in our business strategy or development plans;
our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party
challenges to our patents; commercialization limitations imposed by patents owned or controlled by third
parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection
for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market acceptance of our technology
and products; our ability to successfully manufacture, market and sell our products; the availability of
capital to finance our activities; our ability to restructure and to service our debt obligations; and any other
factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the
Securities and Exchange Commission (“SEC”). For a more thorough discussion of the risks associated with
our business, see the “Risk Factors” section in our annual report for the year ended December 31, 2009
filed with the SEC on Form 10-K, as amended, and our quarterly report for the 3rd quarter of 2010 filed
with the SEC on Form 10-Q.
Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue
reliance on such forward-looking statements. Except as required by law, we disclaim any obligation
to update any such factors or to publicly announce the result of any revisions to any of the forwardlooking
statements contained in this press release to reflect future results, events or developments.
©2010 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device
company. Angiotech discovers, develops and markets innovative treatment solutions for diseases
or complications associated with medical device implants, surgical interventions and acute injury.
To find out more about Angiotech (NASDAQ: ANPI; TSX: ANP), please visit our website at
www.angiotech.com.
FOR ADDITIONAL INFORMATION:
Rick Smith
Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc.
(604) 221-6933
ir@angio.com

Holding... still no idea why

next leg up starting ?

agreed

yeah, I like her too... may be something is on the move behind the scenes... will watch her closely...

i have it on watch bud looks really good

maybe a technical breakout, got some chart alerts yesterday and loaded... hmm... let's watch...

thanks bud

no idea... something cooking?

can you tell me why the big gain today

weeeeeeeeeeeeeeeeeeeee

cawabungaaaaaaa !

And where is the news?

this feels good... finally !!!!!

.36 going

ANPI at.31 today - could there be some good news coming for a change?

ANPI 0.21

ANGIOTECH PHARMACEUTICALS ANNOUNCES PRIVATE LABEL PRODUCT SUPPLY

AGREEMENT WITH HOLOGIC.

Today : Monday 29 November 2010

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANPI) ("Angiotech") announced it has entered into a private label product supply agreement with Hologic, Inc. (NASDAQ: HOLX) ("Hologic") for soft tissue biopsy instruments manufactured by Angiotech. The initial term of the supply agreement is for three years with automatic renewals (subject to certain conditions) for additional periods of three years each. The agreement is specific to products sold in the United States for use in breast biopsies.

In 2009, there were approximately 1.8 million breast biopsies performed in the U.S. The U.S. minimally invasive breast biopsy systems market, which includes vacuum-assisted breast biopsy hand pieces, consoles, and accessories/disposables as well as tissue markers and stereotactic biopsy tables, is estimated at $427M in 2008 according to Elsevier Business Intelligence's Medtech Insight market intelligence reports.

Hologic, a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products specific to women's healthcare, sells a variety of products related to breast biopsy. To expand its product offering and complement its vacuum-assisted breast biopsy systems, Hologic will now offer a 14g single-use, fully automatic biopsy instrument with a number of features including a spring-loaded stylet and cannula, one-handed operation, and an echogenic needle tip. The product will be available with a matching co-axial introducer.

"Angiotech is excited about this partnership with Hologic, a leader in the breast biopsy market," said Dr. William Hunter, President and CEO of Angiotech. "This is yet another example of Angiotech's product development expertise partnered with an industry leader with a broad footprint across the U.S., providing a large number of physicians and patients with Angiotech's innovative healthcare technologies."

VLF

News!!

Does anyone remember whay I bought this one ? I am sure there is a good reason.

I do and company will be able alright....I use 2 years math.....what this company can do in 2 years. Insiders didn't sell a share when price was declining. There is reason for it. Still a lot of time to move that price over $1 so they don't get delisted.
Probably more news coming to push price over $1 .

You do realize they are loaded with debt and have a good chance of going bankrupt. What math are you using to say it is undervalued with 575 million in debt?

Great day.... I am almost up 100% but looking for $2 in year and $4 in 2 years. This stock is way undervalued. Just my opinion.

yes very interesting we need to spread the word

HUGE NEWS OUT from 3 year study ~!!

http://finance.yahoo.com/news/Angiotech-Announces-Three-prnews-2827796061.html?x=0&.v=24

tons of great new recently, lets see the increase in volume next week then anything is possible.

This supposed to go up tomorrow..... If its breaking the .60 resistance, this will see .70's very soon... It has very good news... all seems to be positive....

I'm glad l bought sky is the limit. Imo glta

I had plans to buy this glad i changed my mind